艾立布林治疗乳腺癌的临床研究进展  

Clinical research progress of eribulin in treatment of breast cancer

作　　者：穆轶[1] 缪玮 朱彧 MU Yi;MIAO Wei;ZHU Yu(Department of Pharmacy,the Second Hospital of Tianjin Medical University,TIANJIN 300211,China;Department of Pharmacy,Tianjin Medical University Cancer Hospital,TIANJIN 300060,China;Department of Clinical Laboratory,Tianjin Haihe Hospital,TIANJIN 300350,China)

机构地区：[1]天津医科大学第二医院药学部,天津300211 [2]天津医科大学肿瘤医院药学部,天津300060 [3]天津市海河医院检验科,天津300350

出　　处：《中国新药与临床杂志》2022年第6期331-337,共7页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：艾立布林是一种新型非紫杉烷类微管抑制剂。多项临床试验表明,艾立布林对接受紫杉烷类和蒽环类药物疗效不佳的晚期乳腺癌、人表皮生长因子受体(HER)2阳性和阴性的乳腺癌以及三阴性乳腺癌均具有良好的抗肿瘤作用且安全性更佳。除此之外,艾立布林在乳腺癌的一线治疗和其他类型肿瘤治疗中也有较好的应用前景。Eribulin is a novel non-taxane microtubule dynamics inhibitor.Many clinical trials have shown that eribulin has better anti-tumor effects and safety in patients with advanced breast cancer,human epidermal growth factor receptor(HER)2-positive breast cancer,HER2-negative breast cancer,and triple negative breast cancer which have poor efficacy after receiving taxane and anthracycline treatment.In addition,eribulin also has a good application prospect in the first-line treatment of breast cancer and the treatment of other types of tumors.

关 键 词：艾立布林 乳腺肿瘤 临床研究 

分 类 号：R737.9[医药卫生—肿瘤] R979.1[医药卫生—临床医学]